Clinical trials: Anti-PD-1
QL1706, ESCC
Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
The purpose of this study is to assess the efficacy and safety of QL1706 combined with nab-paclitaxel and cisplatin in first-line therapy for patients with advanced or metastatic esophageal squamous cell carcinoma.
- Conditions
- QL1706, ESCC, First-line Therapy
- Trial name
- NCT07533305
- Testing
- QL1706 plus nab-paclitaxel and cisplatin
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Immune Checkpoint Inhibitors, Lung Cancer
irAE Prediction of Anti-PD-1/L1 in Lung Cancer
the purpose of this study is to identify multi-dimensional immunological biomarkers including cytokines, autoantibodies, and immune cell subtypes of immune-related adverse events (primary) and prognosis(secondary) in the…
- Trial name
- NCT05288569
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking Union Medical College Hospital
Cervical Cancer, Cervical Cancer Metastatic
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)
This is a multicenter, open-label, single-arm study of efficacy, safety and pharmacokinetics of BCD-100 (JSC BIOCAD, Russia) in combination with platinum-based chemotherapy and bevacizumab as first-line treatment in patients with…
- Conditions
- Cervical Cancer, Cervical Cancer Metastatic, Cervical Cancer Recurrent
- Trial name
- NCT03912402
- Testing
- BCD-100, Bevacizumab, Paclitaxel
- Where
- 24 sites in Russia
- Volunteers
- 49 people
- Sponsor
- Biocad
Carcinoma，Non-Small-Cell Lung, Metastatic Lung Cancer
Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC
AIO-YMO/TRK-0415 (FORCE) is a Phase 2, open-label of nivolumab, patients with metastatic non-squamous NSCLC with the necessity of radiotherapy of a metastatic site (e.g.
- Conditions
- Carcinoma，Non-Small-Cell Lung, Metastatic Lung Cancer, Nonsmall Cell Lung Cancer, Lung Adenocarcinoma Metastatic
- Trial name
- FORCE (NCT03044626)
- Testing
- Radiotherapy, Nivolumab
- Where
- 16 sites in Germany
- Volunteers
- 101 people
- Sponsor
- AIO-Studien-gGmbH
Relapsed or Refractory Classical Hodgkin Lymphoma
Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sabestomig (AZD7789) in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL).
- Trial name
- NCT05216835
- Testing
- Sabestomig (AZD7789)
- Where
- 14 sites in United States, Canada and 5 more
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Cancer
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer
JTX-2011-201 is a Phase 2, open label clinical study of vopratelimab (JTX-2011) and ipilimumab in adult subjects with non-small cell lung cancer (NSCLC) or urothelial cancer to evaluate safety and efficacy.
- Trial name
- EMERGE (NCT03989362)
- Testing
- Vopratelimab, Ipilimumab
- Where
- 21 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Jounce Therapeutics, Inc.
Intrahepatic Cholangiocarcinoma
Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma
To explore the objective response rate and safety of toripalimab combined with Gemox in the first-line treatment of progressive, metastatic or unresectable advanced ICC.
- Trial name
- NCT04961788
- Testing
- Gemox combimed PD1 antibody
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
LOCALLY ADVANCED CERVICAL CANCERS
Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC
This study is a clinical study to evaluate the safety and efficacy of Iparomlimab/Tuvonralimab Injection (QL1706, a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies) in Combination With Concurrent…
- Trial name
- NCT07232654
- Testing
- Iparomlimab/Tuvonralimab, Cisplatin, Brachytherapy and External Beam Radiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Carcinoma, Hepatocellular
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of Serplulimab Injection (HLX10, a Recombinant Anti-PD-1 Antibody) and HLX04 (a Biosimilar to Bevacizumab) With…
- Trial name
- NCT06349980
- Testing
- HLX53 (1000mg), HLX53 (2000mg), HLX10
- Where
- China
- Volunteers
- 117 people
- Sponsor
- Shanghai Henlius Biotech
Neoplasms, Rectal
A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer
This study is conducted in adults with rectal cancer that has a certain genetic type. The main goal is to find out whether a longer treatment period with dostarlimab can help more participants have a complete response to…
- Trial name
- DuraSTAR (NCT07740720)
- Testing
- Dostarlimab
- Volunteers
- 90 people
- Sponsor
- GlaxoSmithKline
Cancer of the Head and Neck
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
This is a phase Ib study with a safety lead-in (n = 6 per arm) evaluating combinatorial DPV-001 + sequenced PD-1 blockade, with or without GITR agonist, in recurrent or metastatic HNSCC.
- Trial name
- NCT04470024
- Testing
- INCAGN01876, INCMGA00012, DPV-001
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Providence Health & Services
Solid Cancer
Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1
This is an open labeled, non-randomized adaptive pilot study. The study interventions involved in this study are: Poly-ICLC (Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose, also known as…
- Trial name
- NCT03721679
- Testing
- Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Oncovir, Inc.
Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
The prognosis for patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who refuse or are ineligible for transplant is poor.
- Trial name
- NCT06393361
- Testing
- Chidamide; Decitabine; Anti-PD-1 Antibody, Brentuximab Vedotin, anti-PD-1 antibody.
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Hypopharyngeal Squamous Cell Carcinoma
Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
This clinical trial aims to evaluate the efficacy and safety of Becotatug Vedotin (EGFR-ADC) in combination with Pucotenlimab(Anti-PD-1 Monoclonal Antibody) as neoadjuvant therapy for patients with Resectable Locally Advanced…
- Trial name
- RESERVE-HC (NCT07665190)
- Testing
- Becotatug Vedotin and Pucotenlimab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer
The aim of this study is to evaluate the safety and efficacy of anti PD-1 antibody with radiation therapy in patients with HER2-negative metastatic breast cancer.
- Trial name
- NCT03430479
- Testing
- Cohort A
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Kyoto Breast Cancer Research Network
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Chemotherapy
Toripalimab-based Neoadjuvant Therapy in LA-HNSCC
The objective of research is to evaluate the efficacy and safety of Toripalimab combined with AP regimen in the treatment of resectable locally advanced head and neck squamous cell carcinoma.122 patients were randomly divided…
- Trial name
- NCT05522985
- Testing
- AP combined with or without Toripalimab
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Nsclc
Immune Metabolism Dysregulation and Efficacy to Anti-PD-1 PD-L1 Agents in Non Small Cell Lung Cancer Patients
Prospective, biological, observational study involving the collection and use of samples from patients suffering from NSCLC lung cancer, aimed at comparing the molecular profile related to metabolism among subjects with response…
- Trial name
- NCT07637474
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Regina Elena Cancer Institute
SCLC, Recurrent
Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC
This is a multicenter, open-label, single-arm phase 2 study evaluating the efficacy and safety of ivonescimab combined with paclitaxel polymeric micelles in adults with recurrent or refractory small cell lung cancer after failure…
- Trial name
- NCT07819591
- Testing
- Paclitaxel Polymeric Micelles, Ivonescimab
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Shaodong Hong
Resectable Non-small Cell Lung Cancer
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
AK112, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable NSCLC
- Trial name
- NCT05247684
- Testing
- AK112, Carboplatin, Cisplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Akeso
Advanced Non Small Cell Lung Cancer
Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC
This open-label, multicenter, dose-escalation and expansion trial is designed to evaluate the safety and preliminary efficacy of inhaled DV281 in combination with nivolumabfor the treatment of NSCLC and to select a recommended…
- Trial name
- NCT03326752
- Testing
- DV281, Breath Actuated Nebulizer, DV281 (RP2D)
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Dynavax Technologies Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.